Research Article| Volume 115, ISSUE 2, P140-147, February 1968

A five year progress report on the effectiveness of intraluminal chemotherapy (5-fluorouracil) adjuvant to surgery for colorectal cancer

      This paper is only available as a PDF. To read, Please Download here.


      • 1.
        1. Nationwide survival rates after surgery for cancer of the colon and rectum have not improved in the past twenty years.
      • 2.
        2. The modes of spread of cancer of the colorectum are now well known.
      • 3.
        3. A new combined surgical, intraluminal, and systemic chemotherapy regimen has been evolved in our clinic, hopefully to inhibit tumor spread along these pathways and thus enhance survival rates.
      • 4.
        4. A five year clinical experience using 5-FU intraluminally and systemically has been computer-analyzed.
      • 5.
        5. No apparent improvement in survival rates in stage I and II cases (negative nodes) was indicated in the 5-FU treated group versus nationwide averages.
      • 6.
        6. In the positive node group (stage III) the most significant improvement seemingly develops. At five years the cumulative proportion survival rate is 65 per cent for the 5-FU treated group versus 32 per cent in the nationwide (control) series and 26 per cent in the St. Vincent's Hospital (control) series.
      • 7.
        7. This is only a probing study. The authors well recognize the statistical pitfalls of such a small series of cases in a single institution.
      • 8.
        8. Hopefully a multihospital cooperative project with a double blind randomized study design may be achieved, utilizing upwards of 150 cases yearly.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • James A.G.
        Cancer Prognosis Manual. American Cancer Society, Inc, New York1966
        • Dukes C.
        Surgical pathology of rectal cancer.
        in: Proc. Roy. Soc. Med.37. 1944: 131
        • Dukes C.
        • Bussey H.J.R.
        Venous spread in rectal cancer.
        in: Proc. Roy. Soc. Med.34. 1941: 571
        • Cole W.H.
        • Roberts S.
        • Graham A.L.
        Carcinoma of the colon.
        Arch. Surg. 1965; 91: 547
        • Brown E.
        • Warren S.
        Visceral metastases from rectal carcinoma.
        Surg. Gynec. & Obst. 1938; 66: 611
        • Goligher J.C.
        • Dukes C.
        • Bussey H.J.R.
        Local recurrence after sphincter saving excision for carcinoma of the rectum and rectosigmoid.
        Brit. J. Surg. 1951; 39: 199
        • Southwick H.W.
        • Harridge W.H.
        • Cole W.H.
        Recurrence at the suture line following resection for carcinoma of the colon. Incidence following preventive measures.
        Am. J. Surg. 1962; 103: 86
        • Holden W.D.
        • Dixon W.J.
        • Kingman J.S.
        The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of colorectal carcinoma.
        Ann. Surg. 1967; 165: 481
        • Moss N.H.
        End results in the treatment of cancer of colon and rectum.
        in: Paper presented at the 5th National Cancer Conference, PhiladelphiaSeptember 17, 1964
        • Cole D.R.
        • Rousselot L.M.
        Intravisceral (topical) use of chemotherapeutic (radiomimetic) agents.
        Surgery. 1961; 50: 639
        • Rousselot L.M.
        • Cole D.R.
        • Slattery J.
        • Grossi C.E.
        Intraluminal chemotherapy adjuvant to operation for cancer of the colon and rectum.
        Ann. Surg. 1965; 162: 3
        • Rousselot L.M.
        • Cole D.R.
        • Grossi C.E.
        • Conte A.J.
        • Gonzalez E.M.
        Intraluminal chemotherapy (HN2 or 5-FU) adjuvant to operation for cancer of the colon and rectum. Follow-up report of 97 cases.
        Cancer. 1967; 20: 829
        • Morgan C.N.
        • Lloyd-Davies O.V.
        Discussion on conservative resection in carcinoma of the rectum.
        in: Proc. Roy. Soc. Med.43. 1950: 701
        • Hollinshead W.
        Thoracic, Abdomen and Pelvic.
        in: Anatomy for Surgeon. vol. 2. Hoeber-Harper, New York1956
        • Salsbury A.J.
        • McKinna J.A.
        • Griffiths J.D.
        • et al.
        Circulating cancer cells during excision of carcinomas of the rectum and colon with high ligation of the inferior mesenteric vein.
        Surg. Gynec. & Obst. 1965; 120: 1266
        • Grinnell R.S.
        Results in the treatment of carcinoma of the colon and rectum. An analysis of 2341 cases over a 35 year period with five year survival results in 1667 patients.
        Surg. Gynec. & Obst. 1953; 96: 31
        • Cole D.R.
        • Rousselot L.M.
        • Slattery J.
        • Conte A.J.
        Absorption patterns of intraluminal injected 5-fluorouracil in the isolated right colon of the dog.
        Surgery. 1964; 55: 252
        • Cole D.R.
        • Grossi C.E.
        • Conte A.J.
        • Rousselot L.M.
        Adjuvant intraluminal chemotherapy with 5-fluorouracil in simulated colon cancer in the rat.
        Chemotherapia. 1966; 11: 158
        • Rouvière H.
        Anatome de lymphatiques de l'homme.
        Masson et Cie, Paris1932
        • Cutler S.J.
        • Ederer F.
        Maximum utilization of the life table method in analyzing survival.
        J. Chronic Dis. 1958; 8: 699